Medtronic recently reported second quarter revenue of $4.1 billion, a 6 percent increase over the second quarter of last year, according to a Medtronic news release.
The company reported a 14 percent increase in international revenue, to $1.8 billion, which accounted for 44 percent of Medtronic's worldwide revenue during the second quarter. However, the company's spinal revenue decreased by one percent to $839 million, due to a decrease in domestic sales. International sales for the company's spine business increased 17 percent.
The core spinal revenue, including revenue from metal constructs, interspinous decompression devices and balloon kyphoplasty declined by 3 percent. Biologics in the spine business declined 4 percent, driven by declines in Infuse sales.
The company also reported neuromodulation revenue, which increased by 9 percent to $421 million. This growth was driven by sales of InterStim Therapy, and Activa.
Related Articles on Spine Devices:
Success in the Spine Market: 6 Spine Company Leaders Discuss the Future
InVivo Therapeutics Reports $3M Net Income
RSB Spine Receives Patent for Spinal Fusion Devices
The core spinal revenue, including revenue from metal constructs, interspinous decompression devices and balloon kyphoplasty declined by 3 percent. Biologics in the spine business declined 4 percent, driven by declines in Infuse sales.
The company also reported neuromodulation revenue, which increased by 9 percent to $421 million. This growth was driven by sales of InterStim Therapy, and Activa.
Related Articles on Spine Devices:
Success in the Spine Market: 6 Spine Company Leaders Discuss the Future
InVivo Therapeutics Reports $3M Net Income
RSB Spine Receives Patent for Spinal Fusion Devices